Ohashi Y, Tashiro K, Itoyama Y, Nakano I, Sobue G, Nakamura S, Sumino S, Yanagisawa N
School of Health Sciences and Nursing, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan.
No To Shinkei. 2001 Apr;53(4):346-55.
Amyotrophic lateral sclerosis(ALS) is progressive, degenerative, fatal disease of the motor neuron. No efficacious therapy is available to slow the progressive loss of function, but several new approaches including neurotrophic factors, antioxidants and glutamate antagonists, are currently being evaluated as potential therapies. Mortality, and/or time to tracheostomy, muscle strength and pulmonary function are used as primary endpoints in clinical trials for treatment of ALS. The effect of new therapies on the quality of patients' lives are also important, so we sought to develop a rating scale to measure it. The revised ALS Functional Rating Scale(ALSFRS-R), which has addition of items to ALSFRS to enhance the ability to assess respiratory symptoms, is an assessment determining the degree of impairment in ALS patients' abilities to function independently in activities of daily living. It consists of 12 items to evaluate bulbar function, motor function and respiratory function and each item is scored from 0(unable) to 4(normal). We translated the English score into Japanese one with minor modification considering the inter cultural difference. And we examined reliability of the translated scale. As a measure of reliability, the intraclass correlation coefficient(ICC) was evaluated for total score and the Kappa coefficient proposed by Cohen and Kraemer was calculated for each item. Moreover, we examined sensitivity to clinical change over time and carried out the factor analysis to analyze the factorial structure. The subjects were 27 ALS patients and each was scored twice for reliability or three times for sensitivity by 2 to 5 neurologists and if possible, nurses. The ICC for total score was 0.97(95% C. I.; 0.94-0.98). Extension of the Kappa coefficients were 0.48 to 1.00 for inter-rater reliability and the averaged Kappa coefficients were 0.63 to 1.00 for intra rater reliability, respectively. Concerning the factorial structure, the contribution of the first factor(the first principal component) were 53.5% principal factor solution. The factor loadings of items were 0.52-0.91 except "salivation" and this factor almost equal to the simple sum of all items was interpreted as the general degree of deterioration. The promax votation revealed the riginally supposed factor structure with 3 factors(groups of items): neuromuscuclar function, respiratory function and bulbar function. The rating scale correlated with Global clinical impression of change(GCIC) scored by neurologists and declined with time, indicating its sensitivity to change. On the bases of these results, ALSFRS-R(Japanese version) is considered to be highly reliable enough for clinical use.
肌萎缩侧索硬化症(ALS)是一种进行性、退行性、致命的运动神经元疾病。目前尚无有效的治疗方法来减缓功能的逐渐丧失,但包括神经营养因子、抗氧化剂和谷氨酸拮抗剂在内的几种新方法正在作为潜在疗法进行评估。死亡率和/或气管切开时间、肌肉力量和肺功能被用作ALS治疗临床试验的主要终点。新疗法对患者生活质量的影响也很重要,因此我们试图开发一种评分量表来衡量它。修订后的ALS功能评分量表(ALSFRS-R)在ALSFRS基础上增加了项目,以增强评估呼吸症状的能力,是一种用于确定ALS患者在日常生活活动中独立功能受损程度的评估方法。它由12个项目组成,用于评估延髓功能、运动功能和呼吸功能,每个项目的评分从0(无法完成)到4(正常)。考虑到文化差异,我们对英文评分进行了轻微修改后翻译成日文评分。并且我们检验了翻译后量表的信度。作为信度的一种衡量方法,对总分评估了组内相关系数(ICC),并对每个项目计算了由科恩和克雷默提出的卡帕系数。此外,我们检验了随时间对临床变化的敏感性,并进行了因子分析以分析因子结构。研究对象为27例ALS患者,每位患者由2至5名神经科医生(如有可能还有护士)进行两次评分以评估信度,或进行三次评分以评估敏感性。总分的ICC为0.97(95%置信区间:0.94 - 0.98)。评分者间信度的卡帕系数范围为0.48至1.00,评分者内信度的平均卡帕系数分别为0.63至1.00。关于因子结构,第一个因子(第一主成分)的贡献率在主因子解中为53.5%。除“流涎”外,各项目的因子载荷为0.52 - 0.91,这个几乎等于所有项目简单总和的因子被解释为总体恶化程度。斜交旋转揭示了原本假设的具有3个因子(项目组)的因子结构:神经肌肉功能、呼吸功能和延髓功能。该评分量表与神经科医生给出的整体临床变化印象(GCIC)相关,且随时间下降,表明其对变化的敏感性。基于这些结果,ALSFRS-R(日文版)被认为在临床使用中具有足够高的信度。